# Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer

> **NCT06734182** · PHASE2 · RECRUITING · sponsor: **Guangdong Provincial People's Hospital** · enrollment: 25 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Envafolimab injections+intravenous Disitamab Vedotin+carboplatin

## Key facts

- **NCT ID:** NCT06734182
- **Lead sponsor:** Guangdong Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-22
- **Primary completion:** 2027-06-22
- **Final completion:** 2028-06-22
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2024-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06734182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06734182, "Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06734182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*